Stryker Corporation $SYK Shares Bought by CreativeOne Wealth LLC

CreativeOne Wealth LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 22.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,464 shares of the medical technology company’s stock after buying an additional 999 shares during the period. CreativeOne Wealth LLC’s holdings in Stryker were worth $2,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new position in Stryker in the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Stryker by 66.7% in the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares in the last quarter. ABN AMRO Bank N.V. purchased a new position in shares of Stryker in the 2nd quarter valued at $191,047,000. Finally, Vanguard Group Inc. raised its stake in Stryker by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after acquiring an additional 440,607 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.3%

Shares of Stryker stock opened at $375.11 on Wednesday. The company has a market cap of $143.45 billion, a P/E ratio of 49.68, a PEG ratio of 2.66 and a beta of 0.94. The firm has a fifty day moving average of $369.22 and a two-hundred day moving average of $380.55. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 522,118 shares of company stock worth $185,381,932. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SYK. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Rothschild & Co Redburn started coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Truist Financial boosted their price objective on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research note on Friday, November 14th. Wells Fargo & Company increased their price objective on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Wednesday, November 19th. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $434.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.